ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Elevai Labs Inc

Elevai Labs Inc (ELAB)

0.441
-0.019
( -4.13% )
Actualizado: 10:01:45

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
0.441
Postura de Compra
0.441
Postura de Venta
0.4675
Volume Operado de la Acción
18,661
0.44 Rango del Día 0.4675
0.4311 Rango de 52 semanas 4.2442
Capitalización de Mercado [m]
Precio Anterior
0.46
Precio de Apertura
0.451
Última hora de negociación
10:02:09
Volumen financiero
US$ 8,330
Precio Promedio Ponderado
0.446402
Volumen promedio (3 m)
80,004
Acciones en circulación
18,892,115
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.98
Beneficio por acción (BPA)
-0.23
turnover
1.71M
Beneficio neto
-4.3M

Acerca de Elevai Labs Inc

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed... Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
1970
Elevai Labs Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ELAB. The last closing price for Elevai Labs was US$0.46. Over the last year, Elevai Labs shares have traded in a share price range of US$ 0.4311 to US$ 4.2442.

Elevai Labs currently has 18,892,115 shares in issue. The market capitalisation of Elevai Labs is US$8.69 million. Elevai Labs has a price to earnings ratio (PE ratio) of -1.98.

ELAB Últimas noticias

Oxford Lane Capital Corp. Announces Net Asset Value and Selected Financial Results for the First Fiscal Quarter and Declaration of Distributions on Common Stock for the Months Ending October, November, and December 2024

GREENWICH, Conn., July 26, 2024 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (Nasdaq: OXLC) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGM:...

Oxford Lane Capital Corp. Schedules First Fiscal Quarter Earnings Release and Conference Call for July 26, 2024

GREENWICH, Conn., July 19, 2024 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (Nasdaq: OXLC) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS:...

Oxford Lane Capital Corp. Prices Public Offering of $100,000,000 8.75% Notes Due 2030

GREENWICH, Conn., June 27, 2024 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCM) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ...

Oxford Lane Capital Corp. Announces Offering of Notes

GREENWICH, Conn., June 26, 2024 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCM) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ...

Oxford Lane Capital Corp. Provides May Net Asset Value Update

GREENWICH, Conn., June 07, 2024 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCM) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ...

Oxford Lane Capital Corp. Provides April Net Asset Value Update

GREENWICH, Conn., May 17, 2024 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCM) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS:...

Oxford Lane Capital Corp. Announces Increase in Monthly Common Stock Distributions and Announces Net Asset Value and Selected Financial Results for the Fourth Fiscal Quarter

GREENWICH, Conn., May 14, 2024 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCM) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS:...

Oxford Lane Capital Corp. Schedules Fourth Fiscal Quarter Earnings Release and Conference Call for May 14, 2024

GREENWICH, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (Nasdaq: OXLC) (NasdaqGS: OXLCM) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS:...

Oxford Lane Capital Corp. Provides Preliminary Estimates and Financial Highlights for the Fourth Fiscal Quarter 2024

GREENWICH, Conn., April 17, 2024 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCM) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ...

Oxford Lane Capital Corp. Provides February Net Asset Value Update

GREENWICH, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCM) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.039-8.1250.480.49850.4311739510.44193582CS
4-0.139-23.96551724140.580.59990.4311733410.50070509CS
12-0.244-35.62043795620.6850.70.4311800040.59773399CS
26-0.2567-36.7923176150.69771.04010.43114177840.75180242CS
52-3.559-88.97544.24420.43116537231.1530594CS
156-3.559-88.97544.24420.43116537231.1530594CS
260-3.559-88.97544.24420.43116537231.1530594CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
IMNNImunon Inc
US$ 3.04
(155.46%)
102.59M
ATPCAgape ATP Corporation
US$ 0.1926
(120.11%)
131.64M
TWOU2U Inc
US$ 3.385
(27.74%)
29.53M
PCSAProcessa Pharmaceuticals Inc
US$ 2.1667
(27.45%)
50.97M
CUECue Biopharma Inc
US$ 0.81
(25.23%)
227.47k
QXOQXO Inc
US$ 11.47
(-81.04%)
11.44M
VBIVVBI Vaccines Inc
US$ 0.190201
(-65.81%)
2.61M
CNSPCNS Pharmaceuticals Inc
US$ 0.5901
(-43.26%)
26.73M
BIMIBIMI International Medical Inc
US$ 0.7298
(-37.09%)
277.74k
BLMZBloomZ Inc
US$ 1.78
(-30.74%)
393.84k
ATPCAgape ATP Corporation
US$ 0.1926
(120.11%)
131.64M
NVDANVIDIA Corporation
US$ 107.0886
(-4.03%)
119.77M
IMNNImunon Inc
US$ 3.04
(155.46%)
102.59M
PCSAProcessa Pharmaceuticals Inc
US$ 2.1667
(27.45%)
50.97M
SOFISoFi Technologies Inc
US$ 7.268
(-0.85%)
50.84M

ELAB Discussion

Ver más
FALCON1 FALCON1 3 días hace
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
👍️0
Awl416 Awl416 3 meses hace
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
👍️0
jelaco jelaco 5 meses hace
This stock just can't stay up....someone give this pos some Viagra!
👍️0
IoT II IoT II 5 meses hace
https://stocktwits.com/3227blake/message/562545429
👍️0
Muhbruh Muhbruh 5 meses hace
$ELAB bottom chart 1.8M float no dilution and 6.6 months of cash with 22.07% 13D out today, only 20k short shares left pic.twitter.com/EFsfxgkXqv— STOCKS Gambino (@StocksGambino) February 21, 2024
👍️0
Invest-in-America Invest-in-America 6 meses hace
ELAB: Had skin care Patent, 1-wk. ago; maybe now an outright cure for all CANCERS??? (Joking)
👍️0
IoT II IoT II 6 meses hace
Goodmorning
👍️0
TheFinalCD TheFinalCD 6 meses hace
and then randomly 4am .70-1.65 no news, just some more games

if it breaks 1.65 it could go

otherwise 1 & done pos pump 2.0
👍️0
tw0122 tw0122 6 meses hace
ELAB $1.64 just a quick premarket flip they can do all the dilution they want after 7am..lol
👍️0
TheFinalCD TheFinalCD 6 meses hace
NO THX https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173636262

EVEN THOUGH i MADE A SMALL TRADE AND SOLD 1.49

ELAB IS STILL A POS IMO
👍️0
tw0122 tw0122 6 meses hace
Almost hit 1.30 zones 1.39- 1.60 further up
👍️0
continuity continuity 6 meses hace
Dilution? Total mess.
👍️0
continuity continuity 6 meses hace
Dilution? Total mess.
👍️0
TheFinalCD TheFinalCD 6 meses hace
$ELAB MORE NEWS Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach

https://newsfilter.io/articles/elevai-labs-inc-reports-strong-preliminary-unaudited-financial-performance-for-fiscal-year-2023-high-6ea3644ed452e4ef1c28f33c0f9f63c8
👍️0
airman1 airman1 6 meses hace
Yes, very strange
Morning news Today the/ Shorts piled in:((

ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology

ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-cost

NEWPORT BEACH, Calif., Jan. 16, 2024 -- InvestorsHub NewsWire -- Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce it has signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio, Inc., [Nasdaq: INMB]. The licensing agreement grants Elevai a license to use INmune Bio's proprietary "EMx" technology, developed by INmune Bio, Inc., CMO, Mark Lowdell, PhD, that enables Elevai to manufacture current Good Manufacturing Practice ("cGMP") grade, human umbilical cord-derived mesenchymal stromal cells (hucMSCs) at a lower cost to Elevai than purchasing hucMSCs outright. Manufactured hucMSCs can be incorporated into certain licensed topical cosmetic products sold in the medical aesthetics skincare market.

Elevai believes incorporating the "EMx" technology into its operations is a step towards the company's goal of achieving vertical manufacturing integration, while also expanding long-term production capabilities and lowering overall costs. Ultimately, Elevai believes controlling its processes through its product pipeline with what it believes to be efficient technologies like "EMx" will allow greater stem cell consistency, purity, and propel Elevai's branded cosmetic products further to maintain the company's position as an industry innovator in the medical aesthetics skincare marke
👍️0
TheFinalCD TheFinalCD 6 meses hace
SEC gives no shits

this is exactly why we 100% need Crypto, every share will be tracked every step of the way long or short

now its all a mystery, with offshore BS

cryptonize the stock market to STOP this naked shorting BS

a long time ago one senator wanted to add a serial # like a vin# to every share so companies, and shareholders could account for every share

well crypto enables exactly that, and is fully transparent on the blockchain

#THINKABOUTIT
👍️ 1
airman1 airman1 6 meses hace
Classic chat pump & dump naked short
To 1.00;((
👍️0
continuity continuity 6 meses hace
definitely not a good way to start a business.
👍️0
TheFinalCD TheFinalCD 6 meses hace
LOOKS LIKE NEWS PUMP TO DUMP SHARES IMO

https://elevaiskincare.com/
FLUFFY PUFFY SKIN ..NEWS

OVER EXTENDED POP

GAP & TRAP

BUT -11.11% IS DOWN RIGHT DISGUSTING AFTER BEING UP UP OVER 100% 4.38 HIGH

$ELAB
👍️0
continuity continuity 6 meses hace
this is looking very interesting. The rise is due to the acquisition. Why the fall?
👍️0
IoT II IoT II 6 meses hace
Hello world:)
👍️0
Monksdream Monksdream 6 meses hace
Recent ipo
👍️0

Su Consulta Reciente

Delayed Upgrade Clock